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August 24, 2010:742–6nd points over different periods of time. The patient in the
ignette has an estimated risk as low as 1% for a 10-year fatal
therosclerotic event, but as high as 39% for a lifetime cardiovas-
ular risk. Although this patient’s short-term risk may be low, the
atient’s lifetime risk is quite high and thus should be treated
ccordingly. Additionally, this woman could be categorized as
aving the metabolic syndrome with all 5 inclusion criteria:
besity, elevated triglycerides, low high-density lipoprotein, ele-
ated blood pressure, and abnormal fasting glucose (2).
The first goal for this patient would be lifestyle modification
ith an increase in physical activity and nutrition counseling. If the
ifestyle interventions are not sufficient to reduce her markers of
ncreased risk, it would be reasonable to consider starting her on an
ngiotensin-converting enzyme inhibitor and statin, with the goal
f preventing a first cardiovascular event and overt diabetes (3,4).
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ulse Pressure Amplification as
Predictor of Cardiovascular Risk
e read with interest the paper by Benetos et al. (1) regarding
ulse pressure amplification (PPA) as a predictor of cardiovascular
isk. We fully agree that measured PPA is an important cardiovas-
ular risk marker, because it reflects the level of central systolic/
ulse pressures for any given level of brachial pressures. However,
e would like to challenge the investigators’ conclusion that
omputed PPA based on standard risk factors, without the use of
ctual central pressure measurements, predicts cardiovascular risk
nd that “results were independent of any other confounding
actors.” The investigators generated a regression equation from a
ample of adults (n 834) to predict carotid pulse pressure (CPP). (hey identified age, sex, height, and glycemia as predictors of CPP
fter adjustment for brachial pulse pressure (BPP). The investiga-
ors present a model that predicts CPP with an impressive R2
85.8% predicted variability). However, BPP alone predicted
3.5% of the CPP variability, all the other terms providing as little
s a 2.3% increase in R2 (corresponding to 10% of the CPP
ariability not explained by BPP). The investigators provide no
vidence of the external validity of their equation, proceeding to
pply it to a large population (n  125,151). They concluded that
he estimated carotid/brachial pulse pressure ratio (C/B ratio) was
redictive of cardiovascular and all-cause death and that “results
ere independent of any other confounding factors.” To the degree
hat the estimated C/B ratio is a simple function of BPP and
lassic cardiovascular risk factors, it cannot possibly have true
ndependent value beyond those factors. The calculated C/B ratio
s necessarily correlated with BPP, hence its prognostic value after
djustment for age and sex. The marginal increase in adjusted
tandardized hazard ratios over BPP is likely due to the prognostic
ffect of body height, which is used to estimate the C/B ratio (and
herefore bears an independent association with it). Body height
tself is associated with increased cardiovascular risk (2) and was
ot included in proportional hazards models. Furthermore, the
nvestigators provided no evidence of statistical superiority of
odels including the estimated C/B ratio over those including
PP or any data reflecting actual model performance (such as
kaike’s information criteria or C-statistics). Had the investigators
ompared a model including age, sex, BPP, body height, and
lycemia with a model containing the computed C/B ratio,
rediction of cardiovascular death would have been superior with
he former.
There is a need to continue to gain understanding regarding the
echanisms and the predictive value of central hemodynamics, but
he benefit of PPA as a marker of cardiovascular risk lies in the
arge variability that cannot be predicted by standard risk factors,
herefore requiring actual assessments via pulse wave analysis,
ather than on the relatively small variability that can be predicted
ith the reported regression equation.
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eply
n the past, blood pressure measurements were devoted to the
iagnosis and treatment of threatening accidents. Currently, the
oal of measurements has changed and became prevention, but
he devices remained almost identical. For example, pulse pressure
PP) amplification (1,2), described 50 years ago, is yet poorly used
